| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Over the last 12 months, insiders at Baxter International Inc. have bought $0 and sold $0 worth of Baxter International Inc. stock.
On average, over the past 5 years, insiders at Baxter International Inc. have bought $0 and sold $10.06M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 19,560 shares for transaction amount of $1.61M was made by Martin Sean (SVP and General Counsel) on 2020‑03‑30.
| 2024-03-01 | Sale | Mason Jeanne K | EVP, Chief HR Officer | 64,488 0.0126% | $40.61 | $2.62M | -12.69% | |
| 2023-02-21 | Sale | Kunzler Jacqueline | SVP, Chief Quality Officer | 3,813 0.0008% | $40.50 | $154,427 | -0.37% | |
| 2023-01-17 | Sale | Mason Jeanne K | SVP, Human Resources | 59,477 0.0118% | $44.70 | $2.66M | -8.35% | |
| 2022-04-05 | Sale | STROUCKEN ALBERT P L | 1,215 0.0002% | $76.63 | $93,105 | -26.35% | ||
| 2022-04-05 | Sale | HELLMAN PETER S | 2,827 0.0006% | $75.76 | $214,174 | -26.35% | ||
| 2022-04-01 | Sale | FORSYTH JOHN D | 1,005 0.0002% | $77.68 | $78,068 | -27.92% | ||
| 2022-03-01 | Sale | FORSYTH JOHN D | director | 1,005 0.0002% | $84.82 | $85,244 | -30.01% | |
| 2022-02-28 | Sale | Stevens Brian | SVP, CAO and Controller | 2,500 0.0005% | $85.50 | $213,757 | -30.67% | |
| 2022-02-14 | Sale | Mason Jeanne K | SVP, Human Resources | 54,143 0.0107% | $85.02 | $4.6M | -29.86% | |
| 2022-02-02 | Sale | Chen Thomas F | director | 1,680 0.0003% | $84.53 | $142,010 | -28.82% | |
| 2022-02-01 | Sale | FORSYTH JOHN D | director | 1,005 0.0002% | $85.59 | $86,018 | -27.60% | |
| 2021-11-01 | Sale | Martin Sean | SVP and General Counsel | 21,450 0.0043% | $79.57 | $1.71M | -6.90% | |
| 2021-08-02 | Sale | Martin Sean | SVP and General Counsel | 19,800 0.004% | $77.26 | $1.53M | +2.66% | |
| 2021-04-12 | Sale | Frye Andrew | SVP, President, APAC | 21,998 0.0044% | $84.79 | $1.87M | -3.27% | |
| 2021-04-05 | Sale | STROUCKEN ALBERT P L | director | 9,980 0.0013% | $57.91 | $577,942 | -3.93% | |
| 2021-04-05 | Sale | HELLMAN PETER S | director | 9,980 0.002% | $84.56 | $843,909 | -3.93% | |
| 2020-11-02 | Sale | Martin Sean | SVP and General Counsel | 94,002 0.0184% | $78.67 | $7.4M | +3.35% | |
| 2020-09-14 | Sale | FORSYTH JOHN D | director | 620 <0.0001% | $57.42 | $35,604 | -2.99% | |
| 2020-09-03 | Sale | Kunzler Jacqueline | SVP, Chief Quality Officer | 5,314 0.0011% | $85.87 | $456,313 | -3.31% | |
| 2020-08-03 | Sale | GAVIN JAMES R III | director | 29,798 0.0061% | $86.41 | $2.57M | -1.96% |
| Third Point LLC | director | 23008125 4.4835% | $685.64M | 0 | 5 | |
| Baxter Healthcare SA | 10 percent owner | 2603295 0.5073% | $77.58M | 1 | 0 | <0.0001% |
| KRAEMER HARRY M JANSEN JR | Chairman and | 694556 0.1353% | $20.7M | 1 | 0 | +11.61% |
| PARKINSON ROBERT L JR | Chairman of the Board & CEO | 465485 0.0907% | $13.87M | 2 | 6 | +5.35% |
| TUCKER MICHAEL J | Senior Vice President | 187305 0.0365% | $5.58M | 0 | 1 | |
| ANDERSON BRIAN P | Senior Vice President and | 155427 0.0303% | $4.63M | 0 | 1 | |
| GATLING JAMES M | Corporate Vice President | 151660 0.0296% | $4.52M | 0 | 10 | |
| Mason Jeanne K | EVP, Chief HR Officer | 142290 0.0277% | $4.24M | 0 | 9 | |
| JEHARAJAH NEVILLE J | Corporate Vice President | 127603 0.0249% | $3.8M | 1 | 0 | +8.08% |
| HURLEY JAMES R | Corporate Vice President | 120988 0.0236% | $3.61M | 0 | 1 | |
| Davis Robert M | Corporate Vice President | 120442 0.0235% | $3.59M | 0 | 3 | |
| GREISCH JOHN J | Corporate Vice President | 90419 0.0176% | $2.69M | 2 | 2 | +1.83% |
| HANTSON LUDWIG | Corporate Vice President | 83903 0.0163% | $2.5M | 0 | 3 | |
| Accogli Giuseppe | SVP, President, Americas | 66520 0.013% | $1.98M | 0 | 5 | |
| DROHAN DAVID F | Senior Vice President | 61879 0.0121% | $1.84M | 0 | 1 | |
| Eyre Brik V | SVP, President, Americas | 58993 0.0115% | $1.76M | 0 | 5 | |
| RIEDEL NORBERT G | Corporate Vice President | 52815 0.0103% | $1.57M | 0 | 7 | |
| Martin Sean | SVP and General Counsel | 42281 0.0082% | $1.26M | 1 | 3 | <0.0001% |
| Arduini Peter J | Corporate Vice President | 39855 0.0078% | $1.19M | 0 | 1 | |
| GAVIN JAMES R III | director | 39508 0.0077% | $1.18M | 0 | 8 | |
| Franzi Cristiano | SVP, President, EMEA | 39088 0.0076% | $1.16M | 0 | 1 | |
| DEL SALTO CARLOS | Corporate Vice President | 36289 0.0071% | $1.08M | 0 | 4 | |
| STROUCKEN ALBERT P L | 34127 0.0067% | $1.02M | 6 | 9 | +7.78% | |
| HELLMAN PETER S | 28822 0.0056% | $858,895.60 | 2 | 8 | +15.5% | |
| Baughman Michael J | Corporate Vice President | 27478 0.0054% | $818,844.40 | 0 | 3 | |
| FORSYTH JOHN D | 27029 0.0053% | $805,464.20 | 0 | 18 | ||
| Scharf David P. | Corporate Vice President | 27369 0.0053% | $815,596.20 | 0 | 3 | |
| McGillivray Bruce | Corporate Vice President | 26930 0.0052% | $802,514.00 | 0 | 2 | |
| FOSLER GAIL D | director | 25627 0.005% | $763,684.60 | 0 | 2 | |
| STORM KORNELIS J. | director | 22512 0.0044% | $670,857.60 | 0 | 6 | |
| BOOMER WALTER E | director | 21005 0.0041% | $625,949.00 | 0 | 2 | |
| Utts James E | Corporate Vice President | 20408 0.004% | $608,158.40 | 0 | 2 | |
| Pleau Scott | SVP, Operations | 20076 0.0039% | $598,264.80 | 0 | 3 | |
| White Cheryl L | Corporate Vice President | 16918 0.0033% | $504,156.40 | 0 | 1 | |
| Batchelor Phillip L. | Corporate Vice President | 17083 0.0033% | $509,073.40 | 0 | 4 | |
| Kunzler Jacqueline | SVP, Chief Quality Officer | 16725 0.0033% | $498,405.00 | 0 | 4 | |
| Devitt Blake E | director | 16541 0.0032% | $492,921.80 | 2 | 3 | +4.97% |
| Stevens Brian | SVP, CAO and Controller | 14011 0.0027% | $417,527.80 | 0 | 1 | |
| Chen Thomas F | director | 12987 0.0025% | $387,012.60 | 0 | 1 | |
| HOMBACH ROBERT J. | Corporate Vice President & CFO | 12612 0.0025% | $375,837.60 | 0 | 1 | |
| ALMEIDA JOSE E | Chairman of the Board and CEO | 11691 0.0023% | $348,391.80 | 1 | 0 | +11.45% |
| Shapazian Carole J | director | 9848 0.0019% | $293,470.40 | 0 | 20 | |
| Frye Andrew | SVP, President, APAC | 9041 0.0018% | $269,421.80 | 0 | 3 | |
| MARTIN JOSEPH B | director | 8637 0.0017% | $257,382.60 | 0 | 3 | |
| Bufalino Sebastian J | Corporate Vice President | 6275 0.0012% | $186,995.00 | 0 | 2 | |
| STALLKAMP THOMAS T | director | 4737 0.0009% | $141,162.60 | 0 | 14 |
| Increased Positions | 403 | +41.94% | 36M | +7.36% |
| Decreased Positions | 411 | -42.77% | 28M | -5.83% |
| New Positions | 121 | New | 6M | New |
| Sold Out Positions | 103 | Sold Out | 7M | Sold Out |
| Total Postitions | 953 | -0.83% | 493M | +1.53% |
| Blackrock, Inc. | $2.06M | 13.05% | 66.93M | +3M | +5.32% | 2025-03-31 |
| Vanguard Group Inc | $1.87M | 11.84% | 60.76M | +462,928 | +0.77% | 2024-12-31 |
| Dodge & Cox | $1.55M | 9.82% | 50.38M | +6M | +12.96% | 2024-12-31 |
| Pzena Investment Management Llc | $1.13M | 7.17% | 36.77M | +3M | +9.32% | 2025-03-31 |
| State Street Corp | $669,100.00 | 4.25% | 21.79M | +12,206 | +0.06% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $490,907.00 | 3.12% | 15.99M | +1M | +7.66% | 2024-12-31 |
| Bank Of New York Mellon Corp | $436,147.00 | 2.77% | 14.2M | -1M | -7.53% | 2025-03-31 |
| Geode Capital Management, Llc | $382,245.00 | 2.43% | 12.45M | +290,279 | +2.39% | 2024-12-31 |
| Invesco Ltd. | $288,134.00 | 1.83% | 9.38M | +2M | +19.2% | 2024-12-31 |
| Harris Associates L P | $259,906.00 | 1.65% | 8.46M | -1M | -13.43% | 2024-12-31 |